- $16.19m
- -$40.86m
- $0.19m
Brief: aTyr Pharma Inc Believes Cash Runway Will Extend Into 2026
aTyr Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Airbnb, Coca-Cola, Marriott
Brief: Atyr Pharma Announces Pricing Of Public Offering Of Common Stock
Brief: Atyr Pharma Announces Commencement Of Public Offering Of Common Stock
Brief: aTyr Pharma To Present New Data On Mechanism Of Action Of Efzofitimod At American Thoracic Society 2023 International Conference
Brief: Atyr Pharma Gains E.U. Patent Covering Use Of Efzofitimod With Pirfenidone For Lung Inflammation Or Fibrosis
aTyr Pharma rises on 'orphan drug' tag for lead drug in Europe
Brief: European Commission Grants Orphan Drug Designation For aTyr Pharma’s Efzofitimod For Treatment Of Sarcoidosis
Brief: ATyr Pharma Announces LTBP1 As Target Of DARS TRNA Synthetase Fragment
aTyr Pharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: aTyr Pharma Inc Reports Q3 Loss Per Share Of $0.46
Brief: Atyr Pharma Announces Publication Of Positive Data From Phase 1B/2A Clinical Study Of Efzofitimod
aTyr Pharma Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: Atyr Pharma Inc - Announces Research Collaboration With Dualsystems Biotech AG To Identify 10 New Therapeutic Targets
aTyr Pharma gains as U.S. agency allows patent for antibodies
Brief: aTyr Pharma - Atyr Pharma Announces Notice Of Allowance For U.S. Patent For Anti-Neuropilin-2 (Nrp2) Monoclonal Antibodies
U.S. STOCKS ON THE MOVE-Hasbro, Blackberry, Altamira, Apple
U.S. STOCKS ON THE MOVE-Outlook Therapeutics, DoorDash, Generac